Clinicopathological and prognostic characteristics of CD56-negative multiple myeloma.
We analysed CD56 expression in 70 patients with multiple myeloma (MM) to determine its clinicopathological and prognostic significance. Fifty-five (79%) patients were CD56+. CD56- patients (n = 15) had higher beta2 microglobulin levels and a higher incidence of extramedullary disease, Bence Jones protein, renal insufficiency and thrombocytopenia than CD56+ patients. Their myelomas more frequently had a plasmablastic morphology. Overall survival was significantly lower in CD56- than CD56+ patients (22 vs 63 months, P = 0.0002). We conclude that CD56- MM is a discrete entity associated with more aggressive disease. The higher incidence of plasmablastic cases suggested that CD56- MM may develop from a less mature plasma cell than CD56+ MM.
Sahara
Naohi
N
Internal Medicine III, Hamamatsu University School of Medicine, 1-20-1 Handayama, Hamamatsu-shi, 431-3192 Japan. sahara@hama-med.ac.jp
Takeshita
Akihiro
A
Shigeno
Kazuyuki
K
Fujisawa
Shinya
S
Takeshita
Kaori
K
Naito
Kensuke
K
Ihara
Michio
M
Ono
Takaaki
T
Tamashima
Sadahiro
S
Nara
Kenji
K
Ohnishi
Kazunori
K
Ohno
Ryuzo
R
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001536:Bence Jones Protein / Q000032:analysis; D001854:Bone Marrow Cells / Q000276:immunology*; D019002:CD56 Antigen / Q000032:analysis*; D005260:Female; D005434:Flow Cytometry; D006801:Humans; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000276:immunology* / Q000401:mortality; D010950:Plasma Cells; D011379:Prognosis; D015996:Survival Rate; D001613:beta 2-Microglobulin / Q000032:analysis
D019002:CD56 Antigen; D001613:beta 2-Microglobulin; D001536:Bence Jones Protein